Skip to Main Content
Table II.

Modulation of EAE by α-GalCer in B10.PL Mice


Treatment

No. animals with
 EAE/total no. of animals
 (individual maximal score)

Mean
 disease
 score

Mean
 day
 of onset
Vehicle/PBS 9/10 (5,4,4,4,3,3,3,2,1,0) 2.9 13.2 
Coimmunization
   with α-GalCer 8/8 (5,5,5,5,5,4,4,3) 4.5 12.3 
Preimmunization
   with α-GalCer (1×) 4/8 (4,3,1,1,0,0,0,0) 1.1 11.5 
Preimmunization
   with α-GalCer (3×) 3/9 (4,1,1,0,0,0,0,0) 0.7 13.2 
Preimmunization
   with β-GalCer (1×) 4/4 (4,3,3,3) 3.2 12.7 
Preimmunization
   with α-GalCer (3×)
   plus anti-IL-4 6/6 (5,4,4,3,3,3) 3.3 11.2 
Preimmunization
   with α-GalCer (1×)
   plus control Ig
 
3/4 (2,1,1,0)
 
1.1
 
11.7
 

Treatment

No. animals with
 EAE/total no. of animals
 (individual maximal score)

Mean
 disease
 score

Mean
 day
 of onset
Vehicle/PBS 9/10 (5,4,4,4,3,3,3,2,1,0) 2.9 13.2 
Coimmunization
   with α-GalCer 8/8 (5,5,5,5,5,4,4,3) 4.5 12.3 
Preimmunization
   with α-GalCer (1×) 4/8 (4,3,1,1,0,0,0,0) 1.1 11.5 
Preimmunization
   with α-GalCer (3×) 3/9 (4,1,1,0,0,0,0,0) 0.7 13.2 
Preimmunization
   with β-GalCer (1×) 4/4 (4,3,3,3) 3.2 12.7 
Preimmunization
   with α-GalCer (3×)
   plus anti-IL-4 6/6 (5,4,4,3,3,3) 3.3 11.2 
Preimmunization
   with α-GalCer (1×)
   plus control Ig
 
3/4 (2,1,1,0)
 
1.1
 
11.7
 

Groups of age-matched B10.PL mice were subcutaneously injected with MBPAc1-9/CFA/PT for the induction of EAE and immunized intraperitoneally with glycolipids in the vehicle or with vehicle only, according to coimmunization or preimmunization protocols described in Material and Methods. For the depletion of IL-4, a neutralizing anti-IL-4 monoclonal antibody 11B11 (1 mg/mouse) or a control Rat Ig was administered. Clinical symptoms of EAE were monitored daily.

Close Modal

or Create an Account

Close Modal
Close Modal